New Zealand [RSABE / ABEL]

posted by nobody – 2015-01-31 12:25 (4164 d 22:21 ago) – Posting: # 14334
Views: 26,940

Hi again!

I wanted to learn something about the New Zealand approach to HVD mentioned in Wonnemann, 2014 (largely identical to Wonnemann, 2015 I guess, haven't read it completely yet). Unfortunately I could not find something at the NZ reg homepage, except for a brand new BE guideline, which, however, mentions HVD only in the context of some "isotope application or replicate design" (emphasize by me) studies, apparently without providing further details:

http://www.medsafe.govt.nz/regulatory/Guideline/GRTPNZ/bioequivalence-of-medicines.pdf

However, it apparently allows the use of sequential design "for studies expected to require a large number of subjects" (p. 20/44). But it states that it is "(n)ormally not practical to use more than 40 subjects in a bioavailability study", without any justification for this statement...

This appears pretty close to the design outlined in Wonnemann, 2014 for NZ, but no statistical details are provided in the NZ guideline.


Edit: Subject line changed. [Helmut]

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
335 visitors (0 registered, 335 guests [including 13 identified bots]).
Forum time: 11:47 CEST (Europe/Vienna)

Don’t compromise yourself.
You are all you’ve got.    Janis Joplin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5